Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma Clinical Trial

Official title:

A Dose Escalation Study of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, and Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02303392
• Other study ID #: OSU-14087
• Secondary ID: NCI-2014-01493
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: March 11, 2015
• Est. completion date: December 31, 2022

Study information

• Verified date: April 2022
• Source: Ohio State University Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I trial studies the side effects and best dose of selinexor when given together with ibrutinib in treating patients with chronic lymphocytic leukemia or aggressive non-Hodgkin lymphoma that has returned after a period of improvement or does not respond to treatment. Drugs used in chemotherapy, such as selinexor, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving selinexor together with ibrutinib may be a better treatment for chronic lymphocytic leukemia or aggressive non-Hodgkin lymphoma.

Description:

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose for the combination of selinexor and ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia(SLL)/B-cell prolymphocytic leukemia (PLL) or aggressive non-Hodgkin lymphoma (NHL). SECONDARY OBJECTIVES: I. To characterize the safety and tolerability of the combination of selinexor and ibrutinib in patients with relapsed or refractory CLL/SLL/PLL or aggressive NHL. II. To characterize the pharmacokinetic (PK) properties of the combination of selinexor and ibrutinib in patients with relapsed or refractory CLL/SLL/PLL or aggressive NHL. III. To obtain preliminary evidence on efficacy of the combination of selinexor and ibrutinib in patients with relapsed or refractory CLL/SLL/PLL or aggressive NHL. IV. To obtain preliminary evidence of response in CLL/SLL/PLL and diffuse large B-cell lymphoma (DLBCL) patients receiving the combination of selinexor and ibrutinib as related to CLL/SLL/PLL karyotype and immunoglobulin variable heavy chain (IgVH) mutational status and DLBCL subtype, respectively. V. To evaluate the inhibition of the B-cell receptor signaling pathway in patients with relapsed or refractory CLL/SLL/PLL who receive the combination of selinexor and ibrutinib. VI. To evaluate the change in localization of tumor suppressor and growth regulation proteins in patients with relapsed or refractory CLL/SLL/PLL following treatment with selinexor in general and as related to response. VII. To preliminarily assess potential causes for primary and secondary resistance to selinexor and ibrutinib. VIII. To measure intracellular levels of selinexor and metabolites in peripheral blood mononuclear cells and to identify how this relates to pharmacodynamics effects and clinical outcomes. OUTLINE: This is a dose-escalation study of selinexor. Patients receive ibrutinib orally (PO) on days 8-28 of course 1 and on days 1-28 on subsequent courses and selinexor PO twice daily (BID) weekly on day 1 or bi-weekly on days 1 and 3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 4 weeks and then every 6 months thereafter.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 34
• Est. completion date: December 31, 2022
• Est. primary completion date: April 18, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• A histologically confirmed diagnosis of CLL according the International Workshop on CLL/SLL/B-cell PLL or variant of these (IWCLL or World Health Organization [WHO] Criteria) and meet criteria for treatment or have need for cytoreduction for stem cell transplantation or alternative cell therapy; OR
• A histologically confirmed diagnosis of mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma (DLBCL) de novo or in the setting of transformation from an indolent lymphoma (including DLBCL not otherwise specified) according to the World Health Organization criteria for diagnosis of NHL; AND
• Patients must have received at least one prior therapy for CLL or NHL, need additional treatment, and meet criteria for relapsed or refractory disease; they may not be a candidate for curative therapy; relapsed disease is defined as a patient who previously achieved a complete remission (CR) or a partial remission (PR), but after a period of six or more months demonstrates evidence of disease progression; refractory disease is defined as progression within six months of the last anti-leukemic or anti-lymphoma therapy, or any response less than a CR or PR
• Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2
• Patients with NHL must have objective, documented evidence of disease prior to study entry
• Platelet count >= 50,000/mm^3 in the absence of bone marrow involvement; patients with bone marrow involvement only require a platelet count of 30,000/mm^3
• Absolute neutrophil count >= 1000/mm^3 in the absence of bone marrow involvement
• Creatinine clearance (as calculated by Cockroft Gault equation = [140-age] * mass [kg]/[72 * creatinine mg/dL) >= 30mL/min
• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 times upper limit of normal (ULN)
• Total bilirubin =< 2.0 x ULN
• Female patients capable of reproduction and male patients who have partners capable of reproduction must agree to use an effective contraceptive method during the course of the study and for 2 months following the completion of their last treatment
• Female of childbearing potential must have a negative serum beta-human chorionic gonadotropin (HCG) pregnancy test result within 3 days of first study dose; female patients who are surgically sterilized or who are > 45 years old and have not experienced menses for > 2 years may have beta-HCG pregnancy test waived
• Patients who are hepatitis B polymerase chain reaction (PCR) negative who have a recent (< 6 month) history of intravenous immunoglobulin (IVIG) therapy are eligible; patients with a history of hepatitis B (surface antigen or core antibody positive and PCR positive) must take lamivudine or equivalent drug during study therapy and for one year after completion of all therapy; patients on IVIG who are core antibody positive but PCR negative are not mandated to take prophylaxis
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Patients who are concurrently receiving any other investigational agents
• Patients who have received:
• Radiation or chemotherapy =< 4 weeks
• Mitomycin C, nitrosureas, or radio-immunotherapy =< 6 weeks, or
• Immunotherapy or targeted therapy (such as kinase inhibitors) =< 2 weeks prior to cycle 1 day 1(except patients already on ibrutinib)
• Palliative steroids for disease related symptoms are allowed as long as dose is tapered down to an equivalent of =< 10 mg of oral prednisone daily on cycle 1 day 1
• Patients who have underwent autologous or allogeneic stem cell transplant =< 4 weeks prior to cycle 1 day 1 or have active graft-versus-host disease are excluded
• Patients unable to swallow capsules, those with uncontrolled vomiting or diarrhea or disease significantly affecting gastrointestinal function and/or inhibiting small intestine absorption such as: malabsorption syndrome, resection of the small bowel, or poorly controlled inflammatory bowel disease affecting the small intestine
• Patients who are 20% below their ideal body weight
• Patients must not be receiving systemic anticoagulation with warfarin; patients must be off warfarin for 30 days prior to enrollment; patients who require anticoagulation with an agent other than warfarin will not be excluded, but must be reviewed by the principal investigator prior to enrollment
• As ibrutinib is extensively metabolized by cytochrome P450, family 3, subfamily A, polypeptide 4/5 (CYP3A4/5), and patients must not require continued therapy with a strong inhibitor or inducer of CYP3A4/5
• Patients with active human immunodeficiency virus (HIV) or hepatitis B or C
• Patients with secondary malignancy that requires active systemic therapy that will interfere with interpretation of efficacy or toxicity of selinexor; (Note: patients with basal or squamous skin carcinoma, cervical carcinoma in situ, localized breast cancer requiring hormonal therapy or localized prostate cancer (Gleason score < 5 are allowed)
• Patients with active known central nervous system (CNS) involvement of CLL or lymphoma; (patients with history of CNS CLL or lymphoma now in remission are eligible for the trial)
• Patients who are pregnant or breast feeding; breastfeeding should be discontinued if the mother is treated with selinexor
• Patients must have recovered all toxicities from prior therapy or radiation to grade 1 or less (excluding alopecia)
• Patients may not have had major surgery within 10 days of enrollment, or minor surgery within 7 days of enrollment; examples of minor surgery include dental surgery, insertion of a venous access device, skin biopsy, or aspiration of a joint; the decision about whether a surgery is major or minor can be made at the discretion of the treating physician
• Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Patients with markedly decreased visual acuity

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid
• Leukemia, Prolymphocytic
• Lymphoma
• Lymphoma, Large B-Cell, Diffuse
• Lymphoma, Mantle-Cell
• Prolymphocytic Leukemia
• Recurrent Adult Diffuse Large Cell Lymphoma
• Recurrent Mantle Cell Lymphoma
• Recurrent Small Lymphocytic Lymphoma
• Refractory Chronic Lymphocytic Leukemia

Intervention

Drug:
• Selinexor
Given PO
• Ibrutinib
Given PO

Other:
• Pharmacological Study
Correlative studies
• Laboratory Biomarker Analysis
Correlative studies

Locations

Country	Name	City	State
United States	Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center	Columbus	Ohio
United States	Huntsman Cancer Institute	Salt Lake City	Utah

Sponsors (2)

Lead Sponsor	Collaborator
Jennifer Woyach	Karyopharm Therapeutics Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Pharmacokinetic parameters	Area under the curve, half-life of intervention ( t1/2), clearance, maximum concentration, time to peak concentration, steady state concentration, trough estimation, and estimate t1/2 of accumulation. Measured through blood sample collection and reported as continuous variable. Computed using non-compartmental and compartmental methods and summarized with descriptive statistics.	Course 1 days 1 and 22 (within 10 min before swallowing capsules), at 30 minutes, 1, 2, 4, 8, and 24 hours
Other	Changes in markers of down modulation or inhibition of the B-cell receptor pathway	Markers of down modulation or inhibition of the B-cell receptor pathway including Bruton's tyrosine kinase (BTK) expression and phosphorylation of spleen tyrosine kinase (SYK), v-akt murine thymoma viral oncogene homolog 1 (AKT), and extracellular-signal-regulated kinase (ERK) will be assessed pretreatment and post-treatment where feasible, and reported as a continuous measure.	Baseline to up to 4 years
Other	Change in localization of tumor suppressor and oncogene proteins and messenger ribonucleic acids (mRNAs)	Change in localization of tumor suppressor and oncogene proteins and mRNAs, tumor protein 53 (P53), p73, B-cell lymphoma (Bcl)-2, myc proto-oncogene protein (c-myc), Bcl-6, nuclear factor-kappa B (NF?B)/I kappa B (I?B), forkhead box protein O3 alpha (FOXO3a) and FOXO1 will be measured through blood sample collection, analyzed by immunoblot, and reported as percentage of protein fragments observed in the nucleus at each time point. changes in expression will be explored graphically using boxplots and/or individual line plots, as well as analytically with repeated measures models.	Baseline to up to 4 years
Primary	Dose limiting toxicity assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4 criteria		Day 28
Secondary	Incident of toxicity graded by CTCAE V4	Toxicities will be tabulated by type and grade and displayed in summary form. In addition, the number of courses started/completed, number of patients requiring dose reductions, and the reason for going off treatment may be summarized to assess treatment tolerability.	Up to 4 years
Secondary	Clinical response defined as those with CR or PR measured by International Working Group Criteria for NHL patients and IWCLL 2008 guidelines for CLL patients	The degree of response will be summarized within each stratum and at each dose level.	Up to 4 years
Secondary	Overall response rate (ORR)	Calculated as the number of evaluable responders divided by the total number of evaluable patients. ORR will be presented for those patients treated at the maximum tolerated dose with an exact 90 % confidence interval.	Up to 4 years
Secondary	Progression free survival (PFS)	Kaplan-Meier curves and lifetables of PFS will be generated for each stratum. The 1-year point estimates of PFS will be presented along with standard error.	Date of study enrollment to disease progression or death, whichever occurs first assessed up to 4 years
Secondary	Overall Survival (OS)	Kaplan-Meier curves and lifetables of OS will be generated for each stratum. The 1-year point estimates of OS will be presented along with standard error.	Date of study enrollment to death assessed up to 4 years
Secondary	Response as related to CLL karyotype mutational status		Up to 4 years
Secondary	Response as related to IgVH mutational status		Up to 4 years

External Links

•   The Jamesline